Current Evidence of sacubitril/valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction

References

• Ponikowski P , AnkerSD, VoorsAAet al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 37, 2129–2200 (2016).
   PubMed Web of Science ®Google Scholar
• Wang TJ , EvansJC, BenjaminEJ, LevyD, LeRoyEC, VasanRS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation, 108, 977–982 (2003).
   PubMed Web of Science ®Google Scholar
• Investigators S , YusufS, PittB, DavisCE, HoodWB Jr, CohnJN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med., 327, 685–691 (1992).
   PubMed Web of Science ®Google Scholar
• Butler J , FonarowGC, ZileMRet al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail., 2, 97–112 (2014).
   PubMed Web of Science ®Google Scholar
• Mosterd A , HoesAW. Clinical epidemiology of heart failure. Heart, 93, 1137–1146 (2007).
   PubMed Web of Science ®Google Scholar
• Redfield MM , JacobsenSJ, BurnettJC Jr, MahoneyDW, BaileyKR, RodehefferRJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA, 289, 194–202 (2003).
   PubMed Web of Science ®Google Scholar
• Bleumink GS , KnetschAM, SturkenboomMCJMet al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam study. Eur. Heart J., 25, 1614–1619 (2004).
   PubMed Web of Science ®Google Scholar
• Ceia F , FonsecaC, MotaTet al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J.Heart Fail., 4, 531–539 (2002).
   PubMed Web of Science ®Google Scholar
• Maggioni A , DahlströmU, FilippatosGet al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur. J. Heart Fail., 15, 808–817 (2013).
   PubMed Web of Science ®Google Scholar
• Pocock SJ , AritiCA, McMurrayJJVet al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur. Heart J., 34, 1404–1413 (2013).
   PubMed Web of Science ®Google Scholar
• SOLVD Investigators , YusufS, PittB, DavisCE, HoodWB, CohnN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med., 325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Packer MP , Poole-WilsonA, ArmstrongPWet al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.ATLAS Study Group. Circulation, 100, 2312–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA , SwedbergK, GrangerCBet al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362, 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Cohn JN , TognoniGI Valsartan Heart Failure Trial. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med., 345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA , McMurrayJJV, VelazquezEJet al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med., 349, 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B , ZannadF, RemmeWJet al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Zannad F , McMurrayJJV, KrumHet al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med., 364, 11–21 (2011).
   PubMed Web of Science ®Google Scholar
• Hjalmarson A , GoldsteinS, FagerbergBet al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA, 283, 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Packer M , CoatsAJ, FowlerMBet al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med., 344, 1651–1658 (2001).
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Swedberg K , KomajdaM, BöhmMet al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, 376, 875–885 (2010).
   PubMed Web of Science ®Google Scholar
• Bohm M , BorerJ, FordIet al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol., 102, 11–22 (2013).
   PubMed Web of Science ®Google Scholar
• Antiarrhythmics versus implantable defibrillators investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med., 337, 1576–1583 (1997).
   PubMed Web of Science ®Google Scholar
• Connolly SJ , HallstromAP, CappatoRet al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur. Heart J., 21, 2071–2078 (2000).
   PubMed Web of Science ®Google Scholar
• Cleland JG , AbrahamWT, LindeCet al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur. Heart J., 34, 3547–3556 (2013).
   PubMed Web of Science ®Google Scholar
• Jankowska EA , TkaczyszynM, SuchockiTet al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur. J. Heart Fail., 18, 786–795 (2016).
   PubMed Web of Science ®Google Scholar
• McMurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381, 1995–2008 (2019).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM, BozkurtBet al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol., 68, 1476–1488 (2016).
   PubMed Web of Science ®Google Scholar
• McMurray JJ , PackerM, DesaiASet al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 371, 993–1004 (2014).
   PubMed Web of Science ®Google Scholar
• Akintoye E , BriasoulisA, EgbeAet al. National trends in admission and in-hospital mortality of patients with heart failure in the United States (2001–2014). J.Am. Heart Assoc., 6(12), e006955 (2017).
   PubMed Web of Science ®Google Scholar
• Maisel AS , DuranJM, WetterstenN. Natriuretic peptides in heart failure: atrial and b-type natriuretic peptides. Heart Fail. Clin., 14, 13–25 (2018).
   PubMed Web of Science ®Google Scholar
• Trippodo NC , FoxM, MonticelloTM, PanchalBC, AsaadMM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J. Cardiovasc. Pharmacol., 34, 782–790 (1999).
   PubMed Web of Science ®Google Scholar
• Gu J , NoeA, ChandraPet al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol., 50, 401–414 (2010).
   PubMed Web of Science ®Google Scholar
• Hegde LG , YuC, RennerTet al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J. Cardiovasc. Pharmacol., 57, 495–504 (2011).
   PubMed Web of Science ®Google Scholar
• Monge M , LorthioirA, BobrieG, AziziM. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J. Renin Angiotensin Aldosterone Syst., 14, 285–289 (2013).
   PubMed Web of Science ®Google Scholar
• Ragab MAA , GalalSM, KoranyMA, AhmedAR. First derivative emission spectrofluorimetric method for the determination of LCZ696, a newly approved FDA supramolecular complex of valsartan and sacubitril in tablets. Luminescence, 32, 1417–1425 (2017).
   PubMed Web of Science ®Google Scholar
• Federico C . Natriuretic peptide system and cardiovascular disease. Heart Views, 11, 10–15 (2010).
   PubMedGoogle Scholar
• Menendez JT . The mechanism of action of LCZ696. Card. Fail. Rev., 2, 40–46 (2016).
   PubMedGoogle Scholar
• Ishii M , KaikitaK, SatoKet al. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction. JACC Basic Transl. Sci., 2, 655–668 (2017).
   PubMedGoogle Scholar
• Kenny AJ , BourneA, IngramJ. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J., 291(Pt 1), 83–88 (1993).
   PubMedGoogle Scholar
• Rademaker MT , CharlesCJ, EspinerEA, NichollsMG, RichardsAM, KosoglouT. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin. Sci. (Lond.), 91, 283–291 (1996).
   PubMed Web of Science ®Google Scholar
• Fitzpatrick MA , RademaerMT, CharlesCJet al. Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure. J. Cardiovasc. Pharmacol., 19, 635–640 (1992).
   PubMed Web of Science ®Google Scholar
• Seymour A , AsaadMM, LanoceVM, FennellSA, CheungHS, RogersWL. Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure. Cardiovasc. Res., 27, 1015–1023 (1993).
   PubMed Web of Science ®Google Scholar
• Han Y , AyalasomayajulaS, PanWet al. Pharmacokinetics, safety and tolerability of sacubitril/valsartan (LCZ696) after single-dose administration in healthy Chinese subjects. Eur. J. Drug Metab. Pharmacokinet., 42, 109–116 (2017).
   PubMed Web of Science ®Google Scholar
• Shi J , WangX, NguyenJ, WuAH, BleskeBE, ZhuH-J. Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab. Dispos., 44, 554–559 (2016).
   PubMed Web of Science ®Google Scholar
• Flarakos J , DuY, BedmanTet al. Disposition and metabolism of [(14)C] sacubitril/valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. Xenobiotica, 46, 986–1000 (2016).
   PubMed Web of Science ®Google Scholar
• Waldmeier F , FleschG, MüllerPet al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica, 27, 59–71 (1997).
   PubMed Web of Science ®Google Scholar
• Solomon SD , ClaggettB, DesaiASet al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ. Heart Fail., 9, e002744 (2016).
   PubMed Web of Science ®Google Scholar
• Breathett K , AllenLA, UdelsonJ, DavisG, BristowM. Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction. Circ. Heart Fail., 9(10), e002962 (2016).
   PubMed Web of Science ®Google Scholar
• Tsutsui H , MomomuraS, SaitoYet al. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: rationale for and design of the randomized, double-blind PARALLEL-HF study. J. Cardiol., 70, 225–231 (2017).
   PubMed Web of Science ®Google Scholar
• Jhund PS , ClaggettB, PackerMet al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur. J. Heart Fail., 16, 671–677 (2014).
   PubMed Web of Science ®Google Scholar
• Solomon SD , ZileM, PieskeBet al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a Phase II double-blind randomised controlled trial. Lancet, 380, 1387–1395 (2012).
   PubMed Web of Science ®Google Scholar
• Solomon SD , McMurrayJJV, AnandISet al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med., 381, 1609–1620 (2019).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr , PrescottMF, ButlerJet al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA, 322, 1–11 (2019).
   Web of Science ®Google Scholar
• Chang HY , FengA-N, FongM-Cet al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J. Cardiol., 74, 372–380 (2019).
   PubMed Web of Science ®Google Scholar
• El-Battrawy I , PilsingerC, LiebeVet al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients. J. Clin. Med., 8, doi:10.3390/jcm8101582 (2019).
   PubMed Web of Science ®Google Scholar
• Lopez-Azor JC , vincntL, Valero-MasMJet al. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail., 6, 1161–1166 (2019).
   PubMed Web of Science ®Google Scholar
• Senni M , WachterR, WitteKKet al. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur. J. Heart Fail., 22, 303-312 (2019).
   PubMed Web of Science ®Google Scholar
• Pellicori P , UrbinatiA, ShahPet al. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur. J. Heart Fail., 19, 768–778 (2017).
   PubMed Web of Science ®Google Scholar
• Vardeny O , ClaggettB, PackerMet al. Efficacy of sacubitril/valsartan vs enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur. J. Heart Fail., 18, 1228–1234 (2016).
   PubMed Web of Science ®Google Scholar
• Norberg H , BergdahlE, LindmarkK. Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail., 5, 337–343 (2018).
   PubMed Web of Science ®Google Scholar
• Tsioufis C , GGeorgiopoulos, OikonomouDet al. Hypertension and heart failure with preserved ejection fraction: connecting the dots. Curr. Vasc. Pharmacol., 16, 15–22 (2017).
   PubMed Web of Science ®Google Scholar
• Solomon SD , ClaggettB, McMurrayJJ, HernandezAF, FonarowGC. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur. J. Heart Fail., 18, 1238–1243 (2016).
   PubMed Web of Science ®Google Scholar
• Li Q , LiL, WangFet al. Effect and safety of LCZ696 in the treatment of hypertension: ameta-analysis of 9 RCT studies. Medicine (Baltimore), 98, e16093 (2019).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal D , WachterR, SenniMet al. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs post-discharge initiation of sacubitril/valsartan. ESC Heart Fail., 5, 327–336 (2018).
   PubMed Web of Science ®Google Scholar
• Senni M , McMurrayJJV, WachterRet al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of titration, a double-blind, randomized comparison of two uptitration regimens. Eur. J. Heart Fail., 18, 1193–1202 (2016).
   PubMed Web of Science ®Google Scholar
• Obtulowicz K . Bradykinin-mediated angioedema. Pol. Arch. Med. Wewn., 126, 76–85 (2016).
   PubMed Web of Science ®Google Scholar
• Velazquez EJ , MorrowDA, DeVorADet al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N. Engl. J. Med., 380, 539–548 (2019).
   PubMed Web of Science ®Google Scholar
• Bakris GL , WeirMR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?Arch. Intern. Med., 160, 685–693 (2000).
   PubMed Web of Science ®Google Scholar
• de Diego C , González-TorresL, NúñezJMet al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm, 15, 395–402 (2018).
   PubMed Web of Science ®Google Scholar
• Martens P , NuyensD, Rivero-AyerzaMet al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin. Res. Cardiol., 108, 1074–1082 (2019).
   PubMed Web of Science ®Google Scholar
• Frazier CG , AlexanderKP, NewbyLKet al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J. Am. Coll. Cardiol., 49, 1450–1458 (2007).
   PubMed Web of Science ®Google Scholar
• Ng AC , SindoneAP, WongHS, FreedmanSB. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy. Int. J. Cardiol., 129, 198–204 (2008).
   PubMed Web of Science ®Google Scholar
• Balmforth C , SimpsonJ, ShenLet al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail., 7, 457–465 (2019).
   PubMed Web of Science ®Google Scholar
• Desai AS , McMurrayJJV, PackerMet al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur. Heart J., 36, 1990–1997 (2015).
   PubMed Web of Science ®Google Scholar
• Hopper I , KotechaD, ChinKL, MentzRJ, von LuederTG. Comorbidities in heart failure: are there gender differences?Curr. Heart Fail. Rep., 13, 1–12 (2016).
   PubMedGoogle Scholar
• Gan L , LangenickelT, PetruckJet al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J. Clin. Pharmacol., 56, 78–86 (2016).
   PubMed Web of Science ®Google Scholar
• Jhund PS , FuM, BayramEet al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur. Heart J., 36, 2576–2584 (2015).
   PubMed Web of Science ®Google Scholar
• Joly JM , DesaiAS. Sacubitril/valsartan: from clinical trials to real-world experience. Curr. Treat. Options Cardiovasc. Med., 20, 45 (2018).
   PubMedGoogle Scholar
• Simpson J , JhundPS, SilvaCardoso Jet al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J. Am. Coll. Cardiol., 66, 2059–2071 (2015).
   PubMed Web of Science ®Google Scholar
• Kristensen SL , PreissDS, JhundPSet al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ. Heart Fail., 9, doi:10.1161/CIRCHEARTFAILURE.115.002560 (2016).
   PubMed Web of Science ®Google Scholar
• Okumura N , JhundPS, GongJet al. Effects of sacubitril/valsartan in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to Background therapy. Circ. Heart Fail., 9, doi:10.1161/CIRCHEARTFAILURE.116.003212 (2016).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM, BozkurtBet al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Card. Fail., 23, 628–651 (2017).
   PubMed Web of Science ®Google Scholar